DOCSLIB.ORG

Maintenance Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Commonly Prescribed Maintenance Medications Maintenance (or long-term) medications are those dosage form may be used to treat more than one drugs you may take on a regular basis to treat conditions medical condition. In these cases, each medication may such as high cholesterol, high blood pressure or diabetes. be classified according to its first U.S. Food and Drug Based on your benefit plan, you may get up to a 90-day Administration (FDA) approved use. Some strengths supply of covered maintenance medication delivered and/or formulations listed may not be covered. to you through a home delivery program or at select Please note that oral contraceptives are maintenance retail pharmacies. medications and are part of this list. However, this Some plans may require you to fill these prescriptions list does not include the trade names of all available through home delivery or at select retail pharmacies oral contraceptives because there are a large number in order to receive coverage. of products. Commonly used maintenance medications are listed in Coverage is always subject to the terms and limits of this guide. This list is not all-inclusive and may change your benefit plan. Please verify with your plan if there from time to time. are any additional requirements before a drug may be Most generic drugs listed are followed by a reference covered. For details about your plan, check your benefit brand drug in (parentheses). The brand name drug materials or call the number on your member ID card. in parentheses is listed for reference and may not be Third-party brand names are the property of their covered under your benefit. Some drugs in the same respective owners. ADHD/Stimulants Allergies GALANTAMINE HYDROBROMIDE - galantamine hydrobromide oral atomoxetine hcl cap 10 mg, 18 mg, ipratropium bromide nasal soln soln 4 mg/mL 25 mg, 40 mg, 60 mg, 80 mg, 0.03% (21 mcg/spray), 0.06% 100 mg (base equivalent) (42 mcg/spray) galantamine hydrobromide tab (Strattera) 4 mg (Razadyne) Alzheimer’s Disease clonidine hcl tab er 12hr 0.1 mg galantamine hydrobromide tab ARICEPT - donepezil hydrochloride (Kapvay) 8 mg, 12 mg tab 5 mg, 10 mg, 23 mg guanfacine hcl tab er 24hr 1 mg, memantine hcl cap er 24hr 7 mg, 2 mg, 3 mg, 4 mg donepezil hydrochloride orally 14 mg, 21 mg, 28 mg (base equivalent) (Intuniv) disintegrating tab 5 mg, 10 mg (Namenda xr) INTUNIV - guanfacine hcl tab er 24hr donepezil hydrochloride tab 5 mg, memantine hcl oral solution 1 mg, 2 mg, 3 mg, 4 mg 10 mg, 23 mg (Aricept) 2 mg/mL (base equivalent) EXELON - rivastigmine td patch 24hr memantine hcl tab 5 mg, 10 mg KAPVAY - clonidine hcl tab er 12hr 4.6 mg/24hr, 9.5 mg/24hr, (Namenda) 13.3 mg/24hr 0.1 mg NAMENDA - memantine hcl tab 5 mg, STRATTERA - atomoxetine hcl cap galantamine hydrobromide cap er 10 mg 24hr 8 mg, 16 mg, 24 mg 10 mg, 18 mg, 25 mg, 40 mg, NAMENDA XR - memantine hcl cap er (Razadyne er) 60 mg, 80 mg, 100 mg 24hr 7 mg, 14 mg, 21 mg, 28 mg (base equivalent) BRAND DRUGS generic drugs 1 Commonly Prescribed Maintenance Medications NAMZARIC - memantine hcl- nitroglycerin td patch 24hr propafenone hcl tab 150 mg, donepezil hcl cap er 24hr 7-10 mg, 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 225 mg, 300 mg 14-10 mg, 21-10 mg, 28-10 mg 0.6 mg/hr (Nitro-dur) propafenone hcl cap er 12hr 225 mg, RAZADYNE - galantamine PROCARDIA - nifedipine cap 10 mg 325 mg, 425 mg (Rythmol sr) hydrobromide tab 4 mg RANEXA - ranolazine tab er 12hr quinidine gluconate tab er 324 mg RAZADYNE ER - galantamine 500 mg, 1000 mg QUINIDINE SULFATE - quinidine hydrobromide cap er 24hr 8 mg, ranolazine tab er 12hr 500 mg, sulfate tab 200 mg, 300 mg 16 mg, 24 mg 1000 mg (Ranexa) RYTHMOL SR - propafenone hcl cap rivastigmine tartrate cap er 12hr 225 mg, 325 mg, 425 mg 1.5 mg, 3 mg, 4.5 mg, 6 mg Antiarrhythmics (base equivalent) amiodarone hcl tab 100 mg, sotalol hcl tab 80 mg, 120 mg, 160 mg (Betapace) rivastigmine td patch 24hr 200 mg, 400 mg 4.6 mg/24hr, 9.5 mg/24hr, BETAPACE - sotalol hcl tab 80 mg, sotalol hcl tab 240 mg 13.3 mg/24hr (Exelon) 120 mg, 160 mg sotalol hcl (afib/afl) tab 80 mg, 120 mg, 160 mg (Betapace af) Antiangina BETAPACE AF - sotalol hcl (afib/afl) tab 80 mg, 120 mg, 160 mg SOTYLIZE - sotalol hcl oral solution CARDIZEM - diltiazem hcl tab 30 mg, DIGOXIN - digoxin oral soln 5 mg/mL 60 mg, 120 mg 0.05 mg/mL TIKOSYN - dofetilide cap 125 mcg DILATRATE SR - isosorbide dinitrate (0.125 mg), 250 mcg (0.25 mg), cap er 40 mg digoxin oral soln 0.05 mg/mL (Digoxin) 500 mcg (0.5 mg) diltiazem hcl tab 30 mg, 60 mg, digoxin tab 125 mcg (0.125 mg), 120 mg (Cardizem) Anticoagulants/Antiplatelets 250 mcg (0.25 mg) (Lanoxin) AGGRENOX - aspirin-dipyridamole diltiazem hcl tab 90 mg disopyramide phosphate cap cap er 12hr 25-200 mg ISORDIL TITRADOSE - isosorbide 100 mg, 150 mg (Norpace) dinitrate tab 5 mg, 40 mg AGRYLIN - anagrelide hcl cap 0.5 mg dofetilide cap 125 mcg (0.125 mg), anagrelide hcl cap 0.5 mg (Agrylin) isosorbide dinitrate tab 5 mg, 250 mcg (0.25 mg), 500 mcg 40 mg (Isordil titradose) (0.5 mg) (Tikosyn) anagrelide hcl cap 1 mg isosorbide dinitrate tab 10 mg, flecainide acetate tab 50 mg, aspirin-dipyridamole cap er 12hr 20 mg, 30 mg 100 mg, 150 mg 25-200 mg (Aggrenox) isosorbide mononitrate tab 10 mg, LANOXIN - digoxin tab 62.5 mcg ASPIRIN/OMEPRAZOLE – aspirin- 20 mg (0.0625 mg), 125 mcg (0.125 mg), omeprazole tab delayed release 81-40 mg, 325-40 mg isosorbide mononitrate tab er 250 mcg (0.25 mg) 24hr 30 mg, 60 mg, 120 mg MEXILETINE HCL - mexiletine hcl cap BRILINTA - ticagrelor tab 60 mg, 90 mg nifedipine cap 10 mg (Procardia), 150 mg, 200 mg, 250 mg 20 mg MULTAQ - dronedarone hcl tab cilostazol tab 50 mg, 100 mg NITRO-BID - nitroglycerin oint 2% 400 mg (base equivalent) clopidogrel bisulfate tab 75 mg NITRO-DUR - nitroglycerin td patch NORPACE - disopyramide phosphate (base equivalent) (Plavix) 24hr 0.1 mg/hr, 0.2 mg/hr, 0.3 mg/hr, cap 100 mg, 150 mg dipyridamole tab 25 mg, 50 mg, 0.4 mg/hr, 0.6 mg/hr, 0.8 mg/hr NORPACE CR - disopyramide 75 mg NITRO-TIME – nitroglycerin cap er phosphate cap er 12hr 100 mg, DURLAZA - aspirin capsule er 24hr 2.5 mg, 6.5 mg, 9 mg 150 mg 162.5 mg BRAND DRUGS generic drugs 2 Commonly Prescribed Maintenance Medications EFFIENT - prasugrel hcl tab 5 mg, bupropion hcl tab er 24hr 150 mg, FETZIMA - levomilnacipran hcl cap er 10 mg (base equivalent) 300 mg (Wellbutrin xl) 24hr 20 mg, 40 mg, 80 mg, 120 mg ELIQUIS – apixaban tab 2.5 mg BUPROPION HYDROCHLORIDE ER - (base equivalent) PLAVIX - clopidogrel bisulfate tab bupropion hcl tab er 24hr 450 mg FLUOXETINE DR - fluoxetine hcl cap 75 mg (base equivalent) CAPLYTA – lumateperone tosylate delayed release 90 mg PRADAXA - dabigatran etexilate cap 42 mg FLUOXETINE HYDROCHLORIDE - mesylate cap 75 mg, 150 mg CELEXA - citalopram hydrobromide fluoxetine hcl tab 60 mg (etexilate base equivalent) tab 10 mg, 20 mg, 40 mg fluoxetine hcl (pmdd) tab 10 mg, prasugrel hcl tab 5 mg, 10 mg (base equivalent) 20 mg (Sarafem) (base equivalent) (Effient) citalopram hydrobromide oral fluoxetine hcl cap 10 mg, 20 mg, SAVAYSA - edoxaban tosylate tab soln 10 mg/5 mL 40 mg (Prozac) 15 mg, 30 mg, 60 mg citalopram hydrobromide tab fluoxetine hcl solution 20 mg/5 mL (base equivalent) 10 mg, 20 mg, 40 mg fluoxetine hcl tab 10 mg, 20 mg (base equivalent) (Celexa) XARELTO - rivaroxaban tab 2.5 mg, fluoxetine hcl tab 60 mg 15 mg, 20 mg CYMBALTA - duloxetine hcl enteric (Fluoxetine hcl) YOSPRALA - aspirin-omeprazole tab coated pellets cap 20 mg, 30 mg, 60 mg (base equivalent) fluvoxamine maleate tab 25 mg, delayed release 81-40 mg, 50 mg, 100 mg 325-40 mg DESVENLAFAXINE ER – desvenlafaxine tab er 24hr 50 mg, fluvoxamine maleate cap er 24hr ZONTIVITY - vorapaxar sulfate tab 100 mg, 150 mg 2.08 mg (base equivalent) 100 mg FORFIVO XL - bupropion hcl tab er desvenlafaxine succinate tab er 24hr 450 mg Arterial Disease 24hr 25 mg, 50 mg, 100 mg pentoxifylline tab er 400 mg (base equivalent) (Pristiq) GEODON - ziprasidone hcl cap 20 mg, 40 mg, 60 mg, 80 mg Behavioral Health DRIZALMA SPRINKLE – duloxetine hcl cap delayed release sprinkle INVEGA - paliperidone tab er 24hr ABILIFY - aripiprazole tab 2 mg, 5 mg, 20 mg, 30 mg, 40 mg, 60 mg 1.5 mg, 3 mg, 6 mg, 9 mg 10 mg, 15 mg, 20 mg, 30 mg (base equivalent) LATUDA - lurasidone hcl tab 20 mg, ABILIFY MYCITE - aripiprazole tab duloxetine hcl enteric coated 40 mg, 60 mg, 80 mg, 120 mg 2 mg with sensor, 5 mg with sensor, pellets cap 20 mg, 30 mg, 60 mg 10 mg with sensor, 15 mg with LEXAPRO - escitalopram oxalate tab (base equivalent) (Cymbalta) sensor, 20 mg with sensor, 30 mg 5 mg, 10 mg, 20 mg with sensor duloxetine hcl enteric coated (base equivalent) pellets cap 40 mg APLENZIN - bupropion hbr tab er LITHIUM CARBONATE - lithium (base equivalent) 24hr 174 mg, 348 mg, 522 mg carbonate cap 150 mg, 600 mg EFFEXOR XR - venlafaxine hcl cap er aripiprazole oral solution 1 mg/mL lithium carbonate cap 150 mg, 24hr 37.5 mg, 75 mg, 150 mg 600 mg (Lithium carbonate) aripiprazole orally disintegrating (base equivalent) tab 10 mg, 15 mg lithium carbonate cap 300 mg EMSAM - selegiline td patch 24hr 6 lithium carbonate tab 300 mg aripiprazole tab 2 mg, 5 mg, 10 mg, mg/24hr, 9 mg/24hr, 12 mg/24hr 15 mg, 20 mg, 30 mg (Abilify) lithium carbonate tab er 300 mg escitalopram oxalate soln 5 mg/ (Lithobid) bupropion hcl tab 75 mg, 100 mg 5 mL (base equivalent) lithium carbonate tab er 450 mg bupropion hcl tab er 12hr 100 mg, escitalopram oxalate tab 5 mg, 150 mg, 200 mg (Wellbutrin sr) 10 mg, 20 mg (base equivalent) LITHIUM - lithium oral solution (Lexapro) 8 meq/5 mL BRAND DRUGS generic drugs 3 Commonly Prescribed Maintenance Medications LITHOBID
Recommended publications
  • An Approach to the Patient with a Dry Mouth

    An Approach to the Patient with a Dry Mouth

    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No

    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No

    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
  • Anthem Blue Cross Drug Formulary

    Anthem Blue Cross Drug Formulary

    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al

    US 2003O1086O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu et al. (43) Pub. Date: Jun. 12, 2003 (54) TABLETS AND METHODS FOR MODIFIED (22) Filed: Jul. 8, 2002 RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS Related U.S. Application Data (75) Inventors: James Shunnan Chu, Palo Alto, CA (63) Continuation of application No. 09/599,102, filed on (US); Yisong Yang, Sunnyvale, CA May 19, 2000, now Pat. No. 6,419,954. (US); Joseph A. Fix, Half Moon Bay, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ............................................... A61K 9/20 TOWNSEND AND TOWNSEND AND CREW, (52) U.S. Cl. .............................................................. 424/465 LLP TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) (73) Assignee: Yamanouchi Pharma Technologies, The invention provides a tablet and methods for making the Inc., Palo Alto, CA (US) tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating (21) Appl. No.: 10/191,979 material to modify release of the active agent. Patent Application Publication Jun. 12, 2003 Sheet 1 of 11 US 2003/0108602 A1 (O) N 3(O) 2(O) A/G /A Patent Application Publication Jun. 12, 2003. Sheet 2 of 11 US 2003/0108602 A1 O / O2 OOO OO O Q(SO39 O KC O () i88. OOO OO Okk (ki (k) <k. SJS19O OO <! o O OSS) O O 33 kg) O<< 3k 32 "ooO O & : A/6, 2O Patent Application Publication Jun. 12, 2003 Sheet 3 of 11 US 2003/0108602 A1 Active POWCer (Cevimeline HCI) Formulation Parameters -Pretreatment of Active -Binder: Solid or Solution Binder -% Content of Binder (HPC or PEO/PEG) -Amount of Water Process Parameters -Equipment Selection -Spray Technique Pelletization -Product Temperature (Granulation) -Drying Procedure Process -Milling Technique -High Shear G -Fluid-Bed G In-Process Tests -Yield Active Pellet/Granules -Physical Characteristics -ASSay FIG.
  • Dopamine: a Role in the Pathogenesis and Treatment of Hypertension

    Dopamine: a Role in the Pathogenesis and Treatment of Hypertension

    Journal of Human Hypertension (2000) 14, Suppl 1, S47–S50 2000 Macmillan Publishers Ltd All rights reserved 0950-9240/00 $15.00 www.nature.com/jhh Dopamine: a role in the pathogenesis and treatment of hypertension MB Murphy Department of Pharmacology and Therapeutics, National University of Ireland, Cork, Ireland The catecholamine dopamine (DA), activates two dis- (largely nausea and orthostasis) have precluded wide tinct classes of DA-specific receptors in the cardio- use of D2 agonists. In contrast, the D1 selective agonist vascular system and kidney—each capable of influenc- fenoldopam has been licensed for the parenteral treat- ing systemic blood pressure. D1 receptors on vascular ment of severe hypertension. Apart from inducing sys- smooth muscle cells mediate vasodilation, while on temic vasodilation it induces a diuresis and natriuresis, renal tubular cells they modulate sodium excretion. D2 enhanced renal blood flow, and a small increment in receptors on pre-synaptic nerve terminals influence nor- glomerular filtration rate. Evidence is emerging that adrenaline release and, consequently, heart rate and abnormalities in DA production, or in signal transduc- vascular resistance. Activation of both, by low dose DA tion of the D1 receptor in renal proximal tubules, may lowers blood pressure. While DA also binds to alpha- result in salt retention and high blood pressure in some and beta-adrenoceptors, selective agonists at both DA humans and in several animal models of hypertension. receptor classes have been studied in the treatment of
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals

    Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals

    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
  • AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System

    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome

    Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome

    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
  • Safety Data Sheet

    Safety Data Sheet

    SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water.
  • Urinary Antispasmodics TCO 02.2018

    Urinary Antispasmodics TCO 02.2018

    Therapeutic Class Overview Urinary antispasmodics INTRODUCTION • Overactive bladder (OAB) is defined as urinary urgency, with or without urge incontinence, usually with frequency and nocturia, in the absence of a causative infection or pathological conditions. Urinary incontinence has been shown to greatly reduce quality of life in areas such as mental and general health in addition to physical and social functioning (American Urological Association 2019, Coyne et al 2008, Haab 2014, International Continence Society 2015). Children with OAB usually have detrusor overactivity as diagnosed through cystometric evaluation. Neurogenic detrusor overactivity is predominantly caused by a congenital neural tube defect in children (Austin et al 2016, Franco ○ et al 2020). • Behavioral therapies (eg, bladder training, bladder control strategies, pelvic floor muscle training and fluid management) are considered first-line treatment in all patients with OAB (American Urological Association 2019). • Urinary antispasmodics are used as first-line pharmacological therapy in OAB (American College of Obstetricians and Gynecologists 2015, American Urological Association 2019, Blok et al 2020, Burkhard et al 2018). Anticholinergic therapy has been frequently used in patients with neurogenic detrusor overactivity, but there are limited data in this specific population (Haab 2014). • The○ urinary antispasmodics used for the treatment of OAB belong to 2 classes of drugs, which include anticholinergic compounds known as muscarinic receptor antagonists, and the beta-3 adrenergic agonist (AR), mirabegron. The anticholinergic agents act as antagonists of acetylcholine at muscarinic cholinergic receptors, thereby relaxing smooth muscle in the bladder and decreasing bladder contractions. ○ . Oral immediate-release (IR) and extended-release (ER) formulations (LA, XL, and XR) are available for oxybutynin (Ditropan), tolterodine (Detrol), and trospium.